文献综述

川崎病冠状动脉损伤机制免疫遗传研究进展

  • 邱佳韵(综述) ,
  • 周国平(审校)
展开
  • 南京医科大学第一附属医院儿科(江苏南京 210029)

收稿日期: 2021-12-27

  网络出版日期: 2023-02-16

基金资助

国家自然科学基金项目(81970579)

Immune genetics of coronary artery injury pathogenesis in Kawasaki disease

  • Jiayun Reviewer: QIU ,
  • Guoping Reviser: ZHOU
Expand
  • Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, China

Received date: 2021-12-27

  Online published: 2023-02-16

摘要

川崎病(KD)是以全身性血管炎为主要特征的儿童常见疾病,其最严重的并发症即累及冠状动脉的心血管疾病,即使治疗后,也有部分儿童遗留冠状动脉瘤等后遗症。川崎病已成为儿童获得性心脏病最常见原因之一。目前KD冠状动脉损伤的机制尚不清晰。文章从免疫遗传方向综述国内外KD冠状动脉损伤机制最新研究成果与进展。

本文引用格式

邱佳韵(综述) , 周国平(审校) . 川崎病冠状动脉损伤机制免疫遗传研究进展[J]. 临床儿科杂志, 2023 , 41(1) : 66 -72 . DOI: 10.12372/jcp.2023.21e1773

Abstract

Kawasaki disease (KD) is a kind of common diseases in children mainly characterized by systemic vasculitis. The most serious complication of KD is cardiovascular disease involving coronary arteries. Even after treatment, some children still have sequelae such as coronary aneurysms. KD has become one of the most common causes of acquired heart disease in children. At present, the pathogenesis of KD coronary artery injury is not clear. From the perspective of immunogenetics, the latest research results and progress of coronary artery injury mechanism of KD are reviewed in the article.

参考文献

[1] Zhang Y, Wang Y, Zhang L, et al. Reduced platelet miR-223 induction in Kawasaki disease leads to severe coronary artery pathology through a miR-223/PDGFRbeta vascular smooth muscle cell axis[J]. Circ Res, 2020, 127(7): 855-873.
[2] Kong WX, Ma F Y, Fu SL, et al. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease[J]. World J Pediatr, 2019, 15(2): 168-175.
[3] Kumrah R, Vignesh P, Rawat A, et al. Immunogenetics of Kawasaki disease[J]. Clin Rev Allergy Immunol, 2020, 59(1): 122-139.
[4] Dusenbery SM, Newburger JW, Colan SD, et al. Myocardial fibrosis in patients with a history of Kawasaki disease[J]. Int J Cardiol Heart Vasc, 2021, 32: 100713.
[5] Zeng Z, Wang Q, Yang X, et al. Qishen granule attenuates cardiac fibrosis by regulating TGF-beta /Smad3 and GSK-3beta pathway[J]. Phytomedicine, 2019, 62: 152949.
[6] Ser OS, Cetinkal G, Kilicarslan O, et al. The comparison of serum TGF-beta levels and associated polymorphisms in patients with coronary artery ectasia and normal coronary artery[J]. Egypt Heart J, 2021, 73(1): 32.
[7] Liu Y, Fu L, Pi L, et al. An angiotensinogen gene polymorphism (rs5050) is associated with the risk of coronary artery aneurysm in Southern Chinese children with Kawasaki disease[J]. Dis Markers, 2019: 2849695.
[8] Kwon YC, Kim JJ, Yun SW, et al. Male-specific association of the FCGR2A His167Arg polymorphism with Kawasaki disease[J]. PLoS One, 2017, 12(9): e0184248.
[9] Hoggart C, Shimizu C, Galassini R, et al. Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease[J]. Eur J Hum Genet, 2021, 29(12): 1734-1744.
[10] Paul P, Picard C, Lyonnet L, et al. FCGR2A-HH gene variants encoding the Fc gamma receptor for the C-reactive protein are associated with enhanced monocyte CD32 expression and cardiovascular events' recurrence after primary acute coronary syndrome[J]. Biomedicines, 2022, 10(2): 495.
[11] Calderon-Sanchez EM, Avila-Medina J, Callejo-Garcia P, et al. Role of Orai1 and L-type CaV1.2 channels in Endothelin-1 mediated coronary contraction under ischemia and reperfusion[J]. Cell Calcium, 2020, 86: 102157.
[12] 吴琪. STIM 1/Orai 1信号通路在高压负荷诱导冠状动脉血管平滑肌细胞异常增殖中的机制研究[D]. 南昌大学, 2018.
[13] Ferdosian F, Dastgheib S A, Hosseini-Jangjou SH, et al. Association of TNF-alpha rs1800629, CASP3 rs72689236 and FCGR2A rs1801274 polymorphisms with susceptibility to Kawasaki disease: a comprehensive meta-analysis[J]. Fetal Pediatr Pathol, 2021, 40(4): 320-336.
[14] Ji N, Qi Z, Wang Y, et al. Pyroptosis: a new regulating mechanism in cardiovascular disease[J]. J Inflamm Res, 2021, 14: 2647-2666.
[15] Zhang L, Lin K, Wang Y, et al. Protective effect of TNFRSF11A rs7239667 G > C gene polymorphism on coronary outcome of Kawasaki disease in southern Chinese population[J]. Front Genet, 2021, 12: 691282.
[16] Wang X, Ding YY, Chen Y, et al. MiR-223-3p alleviates vascular endothelial injury by targeting IL6ST in Kawasaki disease[J]. Front Pediatr, 2019, 7: 288.
[17] Dai R, Liu Y, Zhou Y, et al. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention[J]. J Clin Lab Anal, 2020, 34(1): e23013.
[18] Li Y, Wu X, Gao F, et al. MiR-197-3p regulates endothelial cell proliferation and migration by targeting IGF1R and BCL2 in Kawasaki disease[J]. Int J Clin Exp Pathol, 2019, 12(11): 4181-4192.
[19] Liu C, Yang D, Wang H, et al. MicroRNA-197-3p mediates damage to human coronary artery endothelial cells via targeting TIMP3 in Kawasaki disease[J]. Mol Cell Biochem, 2021, 476(12): 4245-4263.
[20] Li Z, Jiang J, Tian L, et al. A plasma mir-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs[J]. PLoS One, 2017, 12(5): e0175407.
[21] Wu S, Sun H, Sun B. MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome[J]. Eur J Med Res, 2020, 25(1): 2.
[22] Ko TM, Chang JS, Chen SP, et al. Genome-wide transcriptome analysis to further understand neutrophil activation and lncRNA transcript profiles in Kawasaki disease[J]. Sci Rep, 2019, 9(1): 328.
[23] Zhang H, Ji N, Gong X, et al. NEAT1/miR-140-3p/MAPK1 mediates the viability and survival of coronary endothelial cells and affects coronary atherosclerotic heart disease[J]. Acta Biochim Biophys Sin (Shanghai), 2020, 52(9): 967-974.
[24] Kim YK. Analysis of circular RNAs in the Coronary arteries of patients with Kawasaki disease[J]. J Lipid Atheroscler, 2019, 8(1): 50-57.
[25] Miao L, Yin RX, Zhang QH, et al. A novel circRNA-miRNA-mRNA network identifies circ-YOD1 as a biomarker for coronary artery disease[J]. Sci Rep, 2019, 9(1): 18314.
[26] Guo X, Liu C, Wang GB, et al. Quantitative proteomics and bioinformatics analyses of human coronary artery endothelial cell injury induced by Kawasaki disease[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2020, 22(7): 796-803.
[27] 蒋丰智, 赵青, 曾俊峰, 等. PTX3及NT-proBNP在小儿川崎病冠脉损害中的意义[J]. 临床儿科杂志, 2019, 37: 107-110.
[28] Ching L L, Nerurkar V R, Lim E, et al. Elevated levels of Pentraxin 3 correlate with neutrophilia and coronary artery dilation during acute Kawasaki disease[J]. Front Pediatr, 2020, 8: 295.
[29] Barbosa JE, Stockler-Pinto MB, Cruz BOD, et al. Nrf2, NF-kappa B and PPAR beta/delta mRNA expression profile in patients with coronary artery disease[J]. Arq Bras Cardiol, 2019, 113(6): 1121-1127.
[30] Qian B, Huang H, Cheng M, et al. Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury[J]. Eur J Med Res, 2020, 25(1): 8.
[31] Zhang D, Liu L, Yuan Y, et al. Oxidative phosphorylation-mediated E-Selectin upregulation is associated with endothelia-monocyte adhesion in human coronary artery endothelial cells treated with sera from patients with Kawasaki disease[J]. Front Pediatr, 2021, 9: 618267.
[32] Wang Y, Hu J, Liu J, et al. The role of Ca(2+)/NFAT in dysfunction and inflammation of human coronary endothelial cells induced by sera from patients with Kawasaki disease[J]. Sci Rep, 2020, 10(1): 4706.
[33] Xiao X, Yang C, Qu SL, et al. S100 proteins in atherosclerosis[J]. Clin Chim Acta, 2020, 502: 293-304.
[34] Zandstra J, van de Geer A, Tanck MWT, et al. Biomarkers for the discrimination of acute Kawasaki disease from infections in childhood[J]. Front Pediatr, 2020, 8: 355.
[35] Armaroli G, Verweyen E, Pretzer C, et al. Monocyte-derived interleukin-1beta as the driver of S100A12-induced sterile inflammatory activation of human coronary artery endothelial cells: implications for the pathogenesis of Kawasaki disease[J]. Arthritis Rheumatol, 2019, 71(5): 792-804.
[36] Nakashima Y, Sakai Y, Mizuno Y, et al. Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease[J]. Cardiovasc Res, 2021, 117(1): 96-108.
[37] He YE, Qiu HX, Wu RZ, et al. Oxidised low-density lipoprotein and its receptor-mediated endothelial dysfunction are associated with coronary artery lesions in Kawasaki disease[J]. J Cardiovasc Transl Res, 2020, 13(2): 204-214.
[38] Wei S, Liu Q. Long noncoding RNA MALAT1 modulates sepsis-induced cardiac inflammation through the miR-150-5p/NF-kappaB axis[J]. Int J Clin Exp Pathol, 2019, 12(9): 3311-3319.
[39] Chang SF, Liu SF, Chen CN, et al. Serum IP-10 and IL-17 from Kawasaki disease patients induce calcification-related genes and proteins in human coronary artery smooth muscle cells in vitro[J]. Cell Biosci, 2020, 10: 36.
[40] Chen X, Wang R, Chen W, et al. Decoy receptor-3 regulates inflammation and apoptosis via PI3K/AKT signaling pathway in coronary heart disease[J]. Exp Ther Med, 2019, 17(4): 2614-2622.
[41] Wu J, Liu C, Zhang L, et al. Histone deacetylase-2 is involved in stress-induced cognitive impairment via histone deacetylation and PI3K/AKT signaling pathway modification[J]. Mol Med Rep, 2017, 16(2): 1846-1854.
[42] Hua L, Zhou Y, Hou C, et al. Shexiang baoxin pills inhibited proliferation and migration of human coronary artery smooth muscle cells via PI3K/AKT/mTOR pathway[J]. Front Cardiovasc Med, 2021, 8: 700630.
[43] Li X, Sun S, Chen D, et al. Puerarin attenuates the endothelial-mesenchymal transition induced by oxidative stress in human coronary artery endothelial cells through PI3K/AKT pathway[J]. Eur J Pharmacol, 2020, 886: 173472.
[44] Shi X, Guan Y, Jiang S, et al. Renin-angiotensin system inhibitor attenuates oxidative stress induced human coronary artery endothelial cell dysfunction via the PI3K/AKT/mTOR pathway[J]. Arch Med Sci, 2019, 15(1): 152-164.
[45] Zhang J, Zhuge Y, Rong X, et al. Protective roles of Xijiao Dihuang Tang on Coronary artery injury in Kawasaki disease[J]. Cardiovasc Drugs Ther, 2021, doi:10.1007/s10557-021-07277-w.
文章导航

/